HTT and Huntington disease: In the R6/2 transgenic mouse model of HD, systemically administration of TUDCA led to reduced striatal atrophy, decreased striatal apoptosis, fewer and smaller size ubiquitinated neuronal intranuclear huntingtin inclusions, and improved locomotor and sensorimotor ability [162].